Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Thieblemont, Catherine; Phillips, Tycel; Ghesquieres, Herve; Y. Cheah, Chan; Roost Clausen, Michael; Cunningham, David; Rok Do, Young; Feldman, Tatyana; Gasiorowski, Robin; Jurczak, Wojciech; Min Kim, Tae; John Lewis, David; van der Poel, Marjolein; Limei Poon, Michelle; Cota Stirner, Mariana; Kilavuz, Nurgul; Chiu, Christopher; Chen, Menghui; Sacchi, Mariana; Elliott, Brian; Ahmadi, Tahamtan; Hutchings, Martin; J. Lugtenburg, Pieternella

doi:10.1200/jco.22.01725

Public

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Shared by NobleBlocks on Apr 20, 2023 • 12:00 AM UTC

Authors:

Catherine Thieblemont

Tycel Phillips

Herve Ghesquieres

Abstract

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!